- Home
- RPT vs ATOS Comparison
RPT vs ATOS Comparison
Compare RPT & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPT
- ATOS
- Stock Information
- Founded
- RPT 2014
- ATOS 2009
- Country
- RPT United States
- ATOS United States
- Employees
- RPT N/A
- ATOS N/A
- Industry
- RPT
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- RPT
- ATOS Health Care
- Exchange
- RPT NYSE
- ATOS Nasdaq
- Market Cap
- RPT 121.7M
- ATOS 107.2M
- IPO Year
- RPT N/A
- ATOS 2012
- Fundamental
- Price
- RPT $2.72
- ATOS $0.94
- Analyst Decision
- RPT Strong Buy
- ATOS Strong Buy
- Analyst Count
- RPT 1
- ATOS 3
- Target Price
- RPT $4.00
- ATOS $6.17
- AVG Volume (30 Days)
- RPT 399.6K
- ATOS 1.5M
- Earning Date
- RPT 08-16-2025
- ATOS 08-11-2025
- Dividend Yield
- RPT 8.81%
- ATOS N/A
- EPS Growth
- RPT N/A
- ATOS N/A
- EPS
- RPT N/A
- ATOS N/A
- Revenue
- RPT N/A
- ATOS N/A
- Revenue This Year
- RPT N/A
- ATOS N/A
- Revenue Next Year
- RPT $19.21
- ATOS N/A
- P/E Ratio
- RPT N/A
- ATOS N/A
- Revenue Growth
- RPT N/A
- ATOS N/A
- 52 Week Low
- RPT $2.29
- ATOS $0.55
- 52 Week High
- RPT $3.86
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- RPT N/A
- ATOS 58.44
- Support Level
- RPT N/A
- ATOS $0.81
- Resistance Level
- RPT N/A
- ATOS $0.88
- Average True Range (ATR)
- RPT 0.00
- ATOS 0.05
- MACD
- RPT 0.00
- ATOS 0.01
- Stochastic Oscillator
- RPT 0.00
- ATOS 84.07
About RPT RITHM PROPERTY TRUST INC
Rithm Property Trust Inc is a real estate investment trust (REIT) externally managed by an affiliate of Rithm Capital Corp. (Rithm). The group is embarking on a new commercial real estate-focused investment. Its tailored approach to investment management seeks to generate attractive risk-adjusted returns for stockholders over the long term through dividends and capital appreciation.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.